Efficacy of a new therapeutic regimen versus two routinely prescribed treatments for eradication of helicobacter pylori: A randomized, double-blind study of doxycycline, co-amoxiclav, and omeprazole in Iranian patients

Digestive Diseases and Sciences

Volumn 54, Issue 3, 2009, Pages 599-603

  Taghavi, Seyed Alireza ^a   Jafari, Ali ^a,c   Eshraghian, Ahad ^a,b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b JAHROM UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Co amoxiclav; Doxycycline; Helicobacter pylori; Omeprazole

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BISMUTH; CLARITHROMYCIN; DOXYCYCLINE; FURAZOLIDONE; OMEPRAZOLE;

ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DYSPEPSIA; ENDOSCOPY; ERADICATION THERAPY; FEMALE; GASTROINTESTINAL INFECTION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; IRAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH BIOPSY;

AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; DOUBLE-BLIND METHOD; DOXYCYCLINE; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IRAN; MALE; OMEPRAZOLE; TREATMENT OUTCOME;

EID: 59449087278     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-008-0374-z     Document Type: Article

References (27)

1. DR Cave 1996 Transmission and epidemiology of Helicobacter pylori Am J Med 100 12 17 10.1016/S0002-9343(96)90004-2
2. FA Wyle 1991 Helicobacter pylori: current perspectives J Clin Gastroenterol 13 114 124 10.1097/00004836-199112001-00020
3. P Ernst 1999 The role of inflammation in the pathogenesis of gastric cancer Aliment Pharmacol Ther 13 13 18 10.1046/j.1365-2036.1999.00003.x
4. JJ Misiewicz 1995 Current insights in the pathogenesis of Helicobacter pylori infection Eur J Gastroenterol Hepatol 7 701 703
5. R Pellicano S Fagoonee M Rizzetto A Ponzetto 2003 Helicobacter pylori and coronary heart disease: which directions for future studies? Crit Rev Microbiol 29 351 359
6. S Massarrat M Saberifiroozi A Soleimani GW Himmelmann M Hitzges H Keshavarz 1995 Peptic ulcer disease, irritable bowel syndrome and constipation in two populations in Iran Eur J Gastroenterol Hepatol 7 427 443
7. KB Bamford J Bickley JS Collins BT Johnston S Potts V Boston 1993 Helicobacter pylori: comparison of DNA fingerprints provides evidence for intrafamilial infection Gut 34 1348 1350 10.1136/gut.34.10.1348
8. HM Malaty L Engstrand NL Pedersen DY Graham 1994 Genetic and environmental influences of Helicobacter pylori infection: a twin study Ann Intern Med 20 982 986
9. HM Malaty DY Graham 1994 Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection Gut 35 742 745 10.1136/gut.35.6.742
10. N Broutet S Tchamgoué E Pereira H Lamouliatte R Salamon F Mégraud 2003 Risk factors for failure of Helicobacter pylori therapy-results of an individual data analysis of 2751 patients Aliment Pharmacol Ther 17 1 99 109 10.1046/j.1365-2036.2003.01396.x
11. MHMG Houben D VandeBeek EF Hensen AJ Craen EA Rauws GN Tytgat 1999 A systematic review of Helicobacter pylori eradication therapy-the impact of antimicrobial resistance on eradication rates Aliment Pharmacol Ther 13 1047 1055 10.1046/j.1365-2036.1999.00555.x
12. N Vakil 2005 Primary and secondary treatment for Helicobacter pylori in the United States Rev Gastroenterol Disord 5 67 72
13. J Kohanteb A Bazargani M Saberi-Firoozi A Mobasser 2007 Antimicrobial susceptibility testing of Helicobacter pylori to selected agents by agar dilution method in Shiraz-Iran Indian J Med Microbiol 25 4 374 377
14. P Malfertheiner F Megraud C O'Morain AP Hungin R Jones A Axon DY Graham G Tytgat 2002 European Helicobacter Pylori Study Group (EHPSG) Aliment Pharmacol Ther 16 167 180 10.1046/j.1365-2036.2002.01169.x
15. H Fakheri R Malekzadeh S Merat M Khatibian A Fazel BZ Alizadeh S Massarrat 2001 Clarithromycin vs furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate Aliment Pharmacol Ther 15 411 416 10.1046/j.1365-2036.2001. 00931.x
16. N Vakil 2006 Helicobacter pylori treatment: a practical approach Am J Gastroenterol 101 497 499 10.1111/j.1572-0241.2006.00454.x
17. F Perri A Qasim L Marras C O'Morain 2003 Treatment of Helicobacter pylori infection Helicobacter 8 53 60 10.1046/j.1523-5378.2003.00162.x
18. KE McColl LS Murray D Gillen A Walker A Wirz J Fletcher C Mowat E Henry A Kelman A Dickson 2002 Randomized trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H. pylori testing alone in the management of dyspepsia BMJ 324 999 1002 10.1136/bmj.324.7344.999
19. N Chiba SJ Van Zanten P Sinclair RA Ferguson S Escobedo E Grace 2002 Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomized controlled trial BMJ 324 1012 1016 10.1136/bmj.324.7344.1012
20. JQ Huang RH Hunt 1995 Treatment after failure. The problem of 'non-responders' Gut 45 140 144
21. PG Farup J Tholfsen S Wetternus R Torp O Hoie OF Lange 2002 Comparison of three triple regimens with omeprazole or ranitidine bismuth citrate for Helicobacter pylori eradication Scand J Gastroenterol 37 1374 1379 10.1080/003655202762671233
22. PH Katelaris GM Forbes NJ Talley B Crotty 2002 A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: the QUADRATE Study Gastroenterology 123 1763 1769
23. GJ Mantzaris K Petraki E Archavlis P Amberiadis P Christoforidis D Kourtessas E Chiotakakou G Triantafyllou 2002 Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study Eur J Gastroenterol Hepatol 14 1237 1243
24. WK Hung WM Wong GS Wong AW Yip ML Szeto KC Lai WH Hu CK Chan HH Xia MF Yuen FM Fung TS Tong VY Ho SK Lam BC Wong 2002 One week ranitidine bismuth citrate, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese Aliment Pharmacol Ther 16 2067 2072
25. A Tursi G Brandimarte G Giorgetti ME Modeo A Gigliobianco 2002 Efficacy and tolerability of ranitidine bismuth citrate plus amoxicillin and clarithromycin as first- or second-line therapy to cure Helicobacter pylori infection Hepatogastroenterology 49 1006 1009
26. H Schwartz R Krause B Sahba M Haber A Weissfeld P Rose N Siepman J Freston 1998 Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double- blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens Am J Gastroenterol 93 584 590
27. F Catalano R Catanzaro C Bentivegna A Brogna G Condorelli R Cipolla 1998 Ranitidine bismuth citrate versus omeprazole triple therapy for the eradication of H. pylori and healing of duodenal ulcer Aliment Pharmacol Ther 12 59 62